Bruce Zetter

Publications

1. Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2. Vaccines (Basel). 2023 Apr 16; 11(4). View Abstract
2. Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation. Mol Cancer Ther. 2023 01 03; 22(1):25-36. View Abstract
3. AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer. Exp Mol Med. 2022 10; 54(10):1713-1726. View Abstract
4. Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis. PLoS One. 2021; 16(11):e0258997. View Abstract
5. Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. Sci Rep. 2021 11 19; 11(1):22630. View Abstract
6. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS One. 2021; 16(4):e0250780. View Abstract
7. Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer. Front Oncol. 2020; 10:594141. View Abstract
8. Prohibitin regulates mTOR pathway via interaction with FKBP8. Front Med. 2021 Jun; 15(3):448-459. View Abstract
9. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021 01; 266:120431. View Abstract
10. Lipidation Approaches Potentiate Adjuvant-Pulsed Immune Surveillance: A Design Rationale for Cancer Nanovaccine. Front Bioeng Biotechnol. 2020; 8:787. View Abstract
11. Developing a novel FRET assay, targeting the binding between Antizyme-AZIN. Sci Rep. 2019 03 15; 9(1):4632. View Abstract
12. Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018 Dec; 2(12):968. View Abstract
13. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018 11; 2(11):850-864. View Abstract
14. Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. Eur J Med Chem. 2018 Jan 20; 144:372-385. View Abstract
15. Prohibitin 1 regulates tumor cell apoptosis via the interaction with X-linked inhibitor of apoptosis protein. J Mol Cell Biol. 2016 06; 8(3):282-5. View Abstract
16. Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. Nat Commun. 2015 Dec 16; 6:8671. View Abstract
17. Biomaterials for mRNA delivery. Biomater Sci. 2015 Dec; 3(12):1519-33. View Abstract
18. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015 Jul-Aug; 21(4):267-73. View Abstract
19. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7779-84. View Abstract
20. Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer. 2014 May 30; 14:387. View Abstract
21. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine. 2014 Jul; 10(5):897-900. View Abstract
22. Advancing treatment of metastatic cancers: from research to communication--where do we need to go? Future Oncol. 2014; 10(9):1535-40. View Abstract
23. Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep. 2013 Nov 06; 3:3151. View Abstract
24. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013 Oct 15; 73(20):6359-74. View Abstract
25. Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential. Clin Exp Metastasis. 2013 Mar; 30(3):237-50. View Abstract
26. Surviving cancer. Nat Med. 2012; 18(6):851. View Abstract
27. Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One. 2012; 7(2):e32191. View Abstract
28. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011 Dec 21; 3(114):114rv3. View Abstract
29. A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis. Oncogene. 2012 May 03; 31(18):2362-72. View Abstract
30. Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo. Amino Acids. 2012 Feb; 42(2-3):549-58. View Abstract
31. Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol Cancer Res. 2011 Oct; 9(10):1285-93. View Abstract
32. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011 Oct 27; 30(43):4386-98. View Abstract
33. Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB J. 2011 Mar; 25(3):907-15. View Abstract
34. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res. 2010 Jun 04; 9(6):3073-82. View Abstract
35. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1362-72. View Abstract
36. Self-assembled gold nanoparticle molecular probes for detecting proteolytic activity in vivo. ACS Nano. 2010 Mar 23; 4(3):1511-20. View Abstract
37. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci U S A. 2010 Feb 09; 107(6):2503-8. View Abstract
38. Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1. Genes Chromosomes Cancer. 2009 Jun; 48(6):502-9. View Abstract
39. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009 Feb 01; 15(3):1024-31. View Abstract
40. The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer. 2008 08; 8(8):647-54. View Abstract
41. Meeting report: innovations in prostate cancer research. Cancer Res. 2008 Feb 01; 68(3):635-8. View Abstract
42. Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification. Oncogene. 2008 Jan 24; 27(5):604-13. View Abstract
43. Assessing enzyme activities using stable isotope labeling and mass spectrometry. Mol Cell Proteomics. 2007 Oct; 6(10):1771-7. View Abstract
44. Thymosin beta-NB is the human isoform of rat thymosin beta15. Ann N Y Acad Sci. 2007 Sep; 1112:286-96. View Abstract
45. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. Clin Cancer Res. 2007 May 01; 13(9):2634-42. View Abstract
46. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism. J Cell Sci. 2006 Jun 15; 119(Pt 12):2583-91. View Abstract
47. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res. 2006 May; 5(5):1224-31. View Abstract
48. Proteomics in tumor progression and metastasis. Ann N Y Acad Sci. 2005 Nov; 1059:1-10. View Abstract
49. Ubiquitin-independent degradation and its implication in cancer. Future Oncol. 2005 Oct; 1(5):567-70. View Abstract
50. Use of thymosin beta15 as a urinary biomarker in human prostate cancer. Prostate. 2005 Jul 01; 64(2):116-27. View Abstract
51. Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem. 2005 Jun; 38(6):558-71. View Abstract
52. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol. 2005 Feb 14; 168(4):643-53. View Abstract
53. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005 Feb; 1(1):37-50. View Abstract
54. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res. 2004 Nov 01; 300(2):297-307. View Abstract
55. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem. 2004 Oct 01; 279(40):41504-11. View Abstract
56. Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines. Cancer Biol Ther. 2004 Jul; 3(7):624-31. View Abstract
57. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics. 2004 Jul; 3(7):729-35. View Abstract
58. Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Res Treat. 2003 Jul; 80(2):139-44. View Abstract
59. Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells. J Biol Chem. 2003 Jun 06; 278(23):20989-94. View Abstract
60. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. 2003 Jan-Feb; 5(1):32-40. View Abstract
61. Cancer. The silence of the genes. Nature. 2002 Oct 10; 419(6907):572-3. View Abstract
62. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther. 2002 Sep-Oct; 1(5):548-53. View Abstract
63. Shifting paradigms in tumor metastasis: challenges and opportunities. Cancer Biol Ther. 2002 Sep-Oct; 1(5):582-5. View Abstract
64. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology. 2002 Feb; 222(2):460-7. View Abstract
65. DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J Biol Chem. 2002 Mar 08; 277(10):7962-9. View Abstract
66. Hold that line. Angiomotin regulates endothelial cell motility. J Cell Biol. 2001 Mar 19; 152(6):F35-6. View Abstract
67. Molecular cloning and structural characterization of the rat thymosin beta15 gene. Gene. 2000 Dec 30; 260(1-2):37-44. View Abstract
68. C-terminal variations in beta-thymosin family members specify functional differences in actin-binding properties. J Cell Biochem. 2000 Mar; 77(2):277-87. View Abstract
69. Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 2000 Jan 27; 19(4):580-91. View Abstract
70. Interaction of the Ras-related protein associated with diabetes rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation. Proc Natl Acad Sci U S A. 1999 Dec 21; 96(26):14911-8. View Abstract
71. Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res. 1999 Dec 15; 59(24):6109-12. View Abstract
72. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol. 1999 Nov; 113(5):838-42. View Abstract
73. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res. 1999 Sep; 58(2):128-36. View Abstract
74. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998 May 12; 95(10):5579-83. View Abstract
75. Thymosin beta15 expression in tumor cell lines with varying metastatic potential. Clin Exp Metastasis. 1998 Apr; 16(3):227-33. View Abstract
76. Angiogenesis and tumor metastasis. Annu Rev Med. 1998; 49:407-24. View Abstract
77. The role of cell motility in prostate cancer. Cancer Metastasis Rev. 1998-1999; 17(4):449-58. View Abstract
78. Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J Biol Chem. 1997 Dec 05; 272(49):30688-92. View Abstract
79. On target with tumor blood vessel markers. Nat Biotechnol. 1997 Nov; 15(12):1243-4. View Abstract
80. Localization and quantitation of expression of the cell motility-related protein thymosin beta15 in human breast tissue. Mod Pathol. 1997 Nov; 10(11):1106-12. View Abstract
81. Isolation of a mouse cDNA encoding mSTI1, a stress-inducible protein containing the TPR motif. Gene. 1997 Jul 31; 194(2):277-82. View Abstract
82. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci. 1997 Apr; 38(5):817-23. View Abstract
83. Stress-inducible, murine protein mSTI1. Characterization of binding domains for heat shock proteins and in vitro phosphorylation by different kinases. J Biol Chem. 1997 Jan 17; 272(3):1876-84. View Abstract
84. Signaling mechanisms in growth factor-stimulated cell motility. Stem Cells. 1997; 15(4):259-67. View Abstract
85. Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med. 1996 Dec; 2(12):1322-8. View Abstract
86. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 1996; 13(1-2):57-64. View Abstract
87. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 1996; 74(6):853-62. View Abstract
88. Cell motility in breast cancer. Cancer Treat Res. 1996; 83:303-23. View Abstract
89. Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat Med. 1995 Oct; 1(10):1040-5. View Abstract
90. The chemotactic response to PDGF-BB: evidence of a role for Ras. J Cell Biol. 1995 Aug; 130(3):725-31. View Abstract
91. Isolation of a mouse cDNA encoding MTJ1, a new murine member of the DnaJ family of proteins. Gene. 1995 Feb 14; 153(2):249-54. View Abstract
92. Increased stem cell factor release by hemangioma-derived endothelial cells. Lab Invest. 1995 Feb; 72(2):166-73. View Abstract
93. Excess early signaling activity inhibits cellular chemotaxis toward PDGF-BB. Oncogene. 1994 May; 9(5):1429-35. View Abstract
94. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature. 1994 Feb 03; 367(6462):474-6. View Abstract
95. Functional domains of the insulin receptor responsible for chemotactic signaling. J Biol Chem. 1994 Jan 07; 269(1):100-4. View Abstract
96. Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Metastasis. 1994-1995; 14(1-6):395-408. View Abstract
97. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993 Aug; 4(4):219-29. View Abstract
98. Laminin regulates a tumor cell chemotaxis receptor through the laminin-binding integrin subunit alpha 6. Cancer Res. 1993 Jun 01; 53(11):2661-6. View Abstract
99. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res. 1993 May 01; 53(9):1971-3. View Abstract
100. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):6197-201. View Abstract
101. Mast cells and angiogenesis. Semin Cancer Biol. 1992 Apr; 3(2):73-9. View Abstract
102. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992 Feb 15; 79(4):958-63. View Abstract
103. The cellular basis for prostate cancer metastasis. Adv Exp Med Biol. 1992; 324:39-43. View Abstract
104. Adhesive interactions in angiogenesis and metastasis. Pharmacol Ther. 1992; 53(2):239-60. View Abstract
105. In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science. 1991 Mar 29; 251(5001):1600-2. View Abstract
106. Multiple ligand binding functions for VLA-2 (alpha 2 beta 1) and VLA-3 (alpha 3 beta 1) in the integrin family. Cell Differ Dev. 1990 Dec 02; 32(3):229-38. View Abstract
107. Cell motility and the extracellular matrix. Curr Opin Cell Biol. 1990 Oct; 2(5):850-6. View Abstract
108. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 01; 1032(1):89-118. View Abstract
109. The cellular basis of site-specific tumor metastasis. N Engl J Med. 1990 Mar 01; 322(9):605-12. View Abstract
110. Cell motility in angiogenesis and tumor metastasis. Cancer Invest. 1990; 8(6):669-71. View Abstract
111. Tumor cell interactions with elastin: implications for pulmonary metastasis. Am Rev Respir Dis. 1989 Nov; 140(5):1458-62. View Abstract
112. Stimulation of mast cell chemotaxis by interleukin 3. J Exp Med. 1989 Oct 01; 170(4):1421-6. View Abstract
113. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest. 1989 Jul; 84(1):43-50. View Abstract
114. Membrane-bound protein kinase C modulates receptor affinity and chemotactic responsiveness of Lewis lung carcinoma sublines to an elastin-derived peptide. J Biol Chem. 1989 Jun 25; 264(18):10614-20. View Abstract
115. Identification of a tumor cell receptor for VGVAPG, an elastin-derived chemotactic peptide. J Cell Biol. 1988 Nov; 107(5):1987-93. View Abstract
116. Angiogenic activity of adipose tissue. Biochem Biophys Res Commun. 1988 May 31; 153(1):347-52. View Abstract
117. Angiogenesis. State of the art. Chest. 1988 Mar; 93(3 Suppl):159S-166S. View Abstract
118. Lewis lung carcinoma variants with differing metastatic specificities adhere preferentially to different defined extracellular matrix molecules. Invasion Metastasis. 1988; 8(2):103-17. View Abstract
119. Human iliac artery endothelial cells express both genes encoding the chains of platelet-derived growth factor (PDGF) and synthesize PDGF-like mitogen. J Cell Physiol. 1987 Aug; 132(2):376-80. View Abstract
120. Monocyte adhesion to subendothelial components. Blood. 1987 Apr; 69(4):1265-8. View Abstract
121. Assay of capillary endothelial cell migration. Methods Enzymol. 1987; 147:135-44. View Abstract
122. Melanoma cell adhesion to defined extracellular matrix components. Biochem Biophys Res Commun. 1986 Sep 14; 139(2):515-22. View Abstract
123. In situ labelling of vascular endothelium with fluorescent acetylated low density lipoprotein. Histochem J. 1985 Dec; 17(12):1309-20. View Abstract
124. Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence. J Cell Biol. 1985 Sep; 101(3):720-4. View Abstract
125. An in vivo assay for chemoattractant activity. Lab Invest. 1985 Sep; 53(3):362-8. View Abstract
126. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol. 1984 Dec; 99(6):2034-40. View Abstract
127. The nonluteal porcine ovary as a source of angiogenic activity. Endocrinology. 1984 Nov; 115(5):1672-7. View Abstract
128. Organ-specific adhesion of metastatic tumor cells in vitro. Science. 1984 Jun 08; 224(4653):1113-5. View Abstract
129. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res. 1983 Dec; 43(12 Pt 1):5857-61. View Abstract
130. Capillary endothelial cell migration: stimulating activity of aqueous humor from patients with ocular cancers. J Natl Cancer Inst. 1983 Sep; 71(3):501-5. View Abstract
131. Stimulation of increased capillary endothelial cell motility by chondrosarcoma cell-derived factors. Cancer Res. 1983 Jul; 43(7):3281-6. View Abstract
132. Retinal vascular endothelial cells and pericytes. Differential growth characteristics in vitro. Invest Ophthalmol Vis Sci. 1983 Apr; 24(4):470-80. View Abstract
133. Cultured endothelial cells derived from the human iliac arteries. In Vitro. 1982 Oct; 18(10):859-66. View Abstract
134. Migration of cultured vascular cells in response to plasma and platelet-derived factors. J Cell Sci. 1982 Aug; 56:71-82. View Abstract
135. In vitro characteristics of endothelium from hemangiomas and vascular malformations. Surgery. 1982 Aug; 92(2):348-53. View Abstract
136. Absence of mast cells in diabetic retinopathy. Microvasc Res. 1982 Jul; 24(1):87-93. View Abstract
137. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med. 1981 Oct 08; 305(15):869-74. View Abstract
138. The stimulation of capillary endothelial cell migration by aqueous humor. J Surg Res. 1981 Mar; 30(3):262-8. View Abstract
139. The endothelial cells of large and small blood vessels. Diabetes. 1981; 30(Suppl 2):24-8. View Abstract
140. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature. 1980 Dec 11; 288(5791):600-2. View Abstract
141. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med. 1980 Oct 01; 152(4):931-44. View Abstract
142. Inhibition of cell motility by interferon. Science. 1980 May 02; 208(4443):516-8. View Abstract
143. Migration of capillary endothelial cells is stimulated by tumour-derived factors. Nature. 1980 May 01; 285(5759):41-3. View Abstract
144. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A. 1979 Oct; 76(10):5217-21. View Abstract
145. LETS protein in normal and pathological human oral epithelium. J Dent Res. 1979 Jan; 58(1):484-8. View Abstract
146. Stimulation of human vascular endothelial cell growth by a platelet-derived growth factor and thrombin. J Supramol Struct. 1979; 11(3):361-70. View Abstract
147. The isolation of vascular endothelial cell lines with altered cell surface and platelet-binding properties. Cell. 1978 Jul; 14(3):501-9. View Abstract
148. Role of the high-molecular-weight glycoprotein in cellular morphology, adhesion, and differentiation. Ann N Y Acad Sci. 1978 Jun 20; 312:299-316. View Abstract
149. Are high-molecular-weight glycoproteins regulators of cellular growth? Ann N Y Acad Sci. 1978 Jun 20; 312:293-8. View Abstract
150. Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol. 1978 Jun; 77(3):774-88. View Abstract
151. Expression of a high molecular weight cell surface glycoprotein (LETS protein) by preimplantation mouse embryos and teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1978 May; 75(5):2324-8. View Abstract
152. Mitogenic response of cells in tissue culture to thrombin. Natl Cancer Inst Monogr. 1978 May; (48):157-65. View Abstract
153. Factors involved in the modulation of cell proliferation in vivo and in vitro: the role of fibroblast and epidermal growth factors in the proliferative response of mammalian cells. In Vitro. 1978 Jan; 14(1):85-118. View Abstract
154. Thrombin potentiates the mitogenic response of cultured fibroblasts to serum and other growth promoting agents. J Cell Physiol. 1977 Aug; 92(2):233-9. View Abstract
155. Binding and internalization of thrombin by normal and transformed chick cells. Proc Natl Acad Sci U S A. 1977 Feb; 74(2):596-600. View Abstract
156. The use of fibroblast and epidermal growth factors to lower the serum requirement for growth of normal diploid cells in early passage: a new method for cloning. Dev Biol Stand. 1976 Dec 13-15; 37:109-30. View Abstract
157. Effects of protease treatment on growth, morphology, adhesion, and cell surface proteins of secondary chick embryo fibroblasts. Cell. 1976 Mar; 7(3):407-12. View Abstract
158. Post-transcriptional regulation of T4 enzyme synthesis. Arch Biochem Biophys. 1974 Jun; 162(2):560-7. View Abstract
159. Evidence that more deoxynucleotide kinase mRNA is transcribed than translated during T4 infection of Escherichia coli. Virology. 1972 Sep; 49(3):808-10. View Abstract
Show All Publications Show Fewer Publications